{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:13:15Z","timestamp":1778274795652,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,8]]},"DOI":"10.7759\/cureus.108508","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:31:15Z","timestamp":1778272275000},"source":"Crossref","is-referenced-by-count":0,"title":["Enhancing Psychiatry Residents\u2019 Knowledge and Comfort With Clozapine Prescribing Through Educational Interventions"],"prefix":"10.7759","author":[{"given":"Christopher","family":"Stewart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faith","family":"Franzwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Stettler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nauman","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawny M","family":"Barnhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane J","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988, 45:789-96. 10.1001\/archpsyc.1988.01800330013001","journal-title":"Arch Gen Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/02698811251319458","article-title":"The mechanism of action of clozapine","volume":"39","author":"Morrison PD","year":"2025","unstructured":"Morrison PD, Jauhar S, Young AH. The mechanism of action of clozapine. J Psychopharmacol. 2025, 39:297-300. 10.1177\/02698811251319458","journal-title":"J Psychopharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22m14587","article-title":"The protective effect of clozapine on suicide: a population mortality study of statewide autopsy records in Maryland","volume":"84","author":"Lee BJ","year":"2023","unstructured":"Lee BJ, Cotes RO, Mojtabai R, Margolis RL, Nucifora FC, Nestadt PS. The protective effect of clozapine on suicide: a population mortality study of statewide autopsy records in Maryland. J Clin Psychiatry. 2023, 84:22m14587. 10.4088\/JCP.22m14587","journal-title":"J Clin Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2016.01.006","article-title":"Treatment-resistant schizophrenia","volume":"39","author":"Elkis H","year":"2016","unstructured":"Elkis H, Buckley PF. Treatment-resistant schizophrenia. Psychiatr Clin North Am. 2016, 39:239-65. 10.1016\/j.psc.2016.01.006","journal-title":"Psychiatr Clin North Am"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-023-01054-z","article-title":"Evaluating monitoring guidelines of clozapine-induced adverse effects: a systematic review","volume":"38","author":"Smessaert S","year":"2024","unstructured":"Smessaert S, Detraux J, Desplenter F, De Hert M. Evaluating monitoring guidelines of clozapine-induced adverse effects: a systematic review. CNS Drugs. 2024, 38:105-23. 10.1007\/s40263-023-01054-z","journal-title":"CNS Drugs"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00932-2","article-title":"A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia","volume":"36","author":"Correll CU","year":"2022","unstructured":"Correll CU, Agid O, Crespo-Facorro B, de Bartolomeis A, Fagiolini A, Sepp\u00e4l\u00e4 N, Howes OD. A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia. CNS Drugs. 2022, 36:659-79. 10.1007\/s40263-022-00932-2","journal-title":"CNS Drugs"},{"key":"ref7","unstructured":"U.S. Food and Drug Administration. Risk Evaluation and Mitigation Strategy (REMS) for clozapine products. (2024). Accessed. May 2, 2026: https:\/\/www.fda.gov\/media\/183654\/download."},{"key":"ref8","unstructured":"FDA removes risk evaluation and mitigation strategy (REMS) program for the antipsychotic drug clozapine. (2025). Accessed. May 3, 2026: https:\/\/www.fda.gov\/drugs\/drug-safety-communications\/fda-removes-risk-evaluation-and-mitigation-strategy-rems-program...."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.1155","article-title":"FDA eliminates the clozapine REMS-what comes next?","volume":"82","author":"Kelly DL","year":"2025","unstructured":"Kelly DL, Kane JM, Love RC, Cotes RO. FDA eliminates the clozapine REMS-what comes next?. JAMA Psychiatry. 2025, 82:751-2. 10.1001\/jamapsychiatry.2025.1155","journal-title":"JAMA Psychiatry"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2024.04.012","article-title":"Overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: a narrative review and recommendation for clinical practice","volume":"84","author":"Agid O","year":"2024","unstructured":"Agid O, Crespo-Facorro B, de Bartolomeis A, Fagiolini A, Howes OD, Sepp\u00e4l\u00e4 N, Correll CU. Overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: a narrative review and recommendation for clinical practice. Eur Neuropsychopharmacol. 2024, 84:35-47. 10.1016\/j.euroneuro.2024.04.012","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2025.10421","article-title":"Examining the safety profile of clozapine versus other antipsychotics: systematic review and meta-analysis","volume":"Online ahead of print","author":"Pinioti E","year":"2025","unstructured":"Pinioti E, Glarou E, Lappas AS, et al.. Examining the safety profile of clozapine versus other antipsychotics: systematic review and meta-analysis. Br J Psychiatry. 2025, Online ahead of print:1-10. 10.1192\/bjp.2025.10421","journal-title":"Br J Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-14-102","article-title":"Clozapine: a review of clinical practice guidelines and prescribing trends","volume":"14","author":"Warnez S","year":"2014","unstructured":"Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry. 2014, 14:102. 10.1186\/1471-244X-14-102","journal-title":"BMC Psychiatry"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s40670-020-01131-8","article-title":"A rapid review of prescribing education interventions","volume":"31","author":"Omer U","year":"2021","unstructured":"Omer U, Danopoulos E, Veysey M, Crampton P, Finn G. A rapid review of prescribing education interventions. Med Sci Educ. 2021, 31:273-89. 10.1007\/s40670-020-01131-8","journal-title":"Med Sci Educ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2026.3050","article-title":"Brief prescribing support and buprenorphine adoption in rural primary care: a cluster randomized clinical trial","volume":"9","author":"Franz B","year":"2026","unstructured":"Franz B, Dhanani LY, Brook D, et al.. Brief prescribing support and buprenorphine adoption in rural primary care: a cluster randomized clinical trial. JAMA Netw Open. 2026, 9:e263050. 10.1001\/jamanetworkopen.2026.3050","journal-title":"JAMA Netw Open"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13111","article-title":"How and when to use clozapine","volume":"141","author":"Rubio JM","year":"2020","unstructured":"Rubio JM, Kane JM. How and when to use clozapine. Acta Psychiatr Scand. 2020, 141:178-89. 10.1111\/acps.13111","journal-title":"Acta Psychiatr Scand"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201700162","article-title":"Addressing barriers to clozapine underutilization: a national effort","volume":"69","author":"Kelly DL","year":"2018","unstructured":"Kelly DL, Freudenreich O, Sayer MA, Love RC. Addressing barriers to clozapine underutilization: a national effort. Psychiatr Serv. 2018, 69:224-7. 10.1176\/appi.ps.201700162","journal-title":"Psychiatr Serv"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2007.04.008","article-title":"Real-world antipsychotic treatment practices","volume":"30","author":"Moore TA","year":"2007","unstructured":"Moore TA, Covell NH, Essock SM, Miller AL. Real-world antipsychotic treatment practices. Psychiatr Clin North Am. 2007, 30:401-16. 10.1016\/j.psc.2007.04.008","journal-title":"Psychiatr Clin North Am"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291721000246","article-title":"Demographic and clinical variables associated with response to clozapine in schizophrenia: a systematic review and meta-analysis","volume":"51","author":"Griffiths K","year":"2021","unstructured":"Griffiths K, Millgate E, Egerton A, MacCabe JH. Demographic and clinical variables associated with response to clozapine in schizophrenia: a systematic review and meta-analysis. Psychol Med. 2021, 51:376-86. 10.1017\/S0033291721000246","journal-title":"Psychol Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-023-05176-y","article-title":"Long-term outcomes of delayed clozapine initiation in treatment-resistant schizophrenia: a multicenter retrospective cohort study","volume":"23","author":"Hatano M","year":"2023","unstructured":"Hatano M, Kamei H, Takeuchi I, et al.. Long-term outcomes of delayed clozapine initiation in treatment-resistant schizophrenia: a multicenter retrospective cohort study. BMC Psychiatry. 2023, 23:673. 10.1186\/s12888-023-05176-y","journal-title":"BMC Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/449282-enhancing-psychiatry-residents-knowledge-and-comfort-with-clozapine-prescribing-through-educational-interventions","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:31:17Z","timestamp":1778272277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/449282-enhancing-psychiatry-residents-knowledge-and-comfort-with-clozapine-prescribing-through-educational-interventions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.108508","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,8]]}}}